Servier is an independent Group governed by a non-profit foundation, with our headquarters in France. Operating in 150 countries, we have 22,500 employees worldwide and a revenue of 4.7 billion euros in 2019. Entirely independent, we invest each year over 20% of our total revenue, excluding generic activities, into Research and Development, and all profits are used for further development. Our R&D is focused on five main therapeutic areas: cardiovascular diseases, diabetes, cancer, neuropsychiatric diseases, and immune-inflammatory diseases. We have 16 clinical and pharmaceutical manufacturing centers worldwide which produce more than 600 million boxes of medicines, each year.

Servier entered the Bulgarian market 27 years ago. Today Servier is a care leader in providing highly effective therapies for diabetes, cardiovascular diseases and chronic venous disease in the country. Its ambition is to become a renowned and innovative player in oncology too. We have been working closely with healthcare professionals, scientific societies, patient organisations and institutions in order to improve the quality of life among patients in Bulgaria.

In Servier we have been committed to therapeutic progress to serve patient needs. We strive to transmit to future generations a world that can ensure access to quality health care for all.